comparemela.com

Latest Breaking News On - Yakun wang - Page 1 : comparemela.com

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies.

United statesChunlei liValerie malyvanh jansenYakun wangElevation oncology incCorporate communications investor relationsAmerican society of clinical oncologyPrnewswire elevation oncology incExchange commissionGroup limitedDrug administrationAmerican societyClinical oncologyChief medical officerElevation oncologyChief scientific officer

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies.

United statesValerie malyvanh jansenYakun wangCorporate communications investor relationsElevation oncology incGroup limitedDrug administrationAmerican society of clinical oncologyPrnewswire elevation oncology incExchange commissionAmerican societyClinical oncologyElevation oncologyChief medical officerPoster discussionMolecularly targeted agents

QureBio Ltd to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings

/PRNewswire/ QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered.

Xiangdong quJian zhangLin shenSan franciscoUnited statesYuping sunViva bioXiaohua chenTao yuYanqiao zhangJie houLi weiYusheng wangQin yuJifang gongYakun wang

vimarsana © 2020. All Rights Reserved.